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Abstract
Objectives: There is controversy about the roles of locoregional therapies in patients with liver metas-
tases from breast cancer (LMBC). The aim of this study was to analyse survival after laparoscopic
radiofrequency ablation (RFA) of LMBC and to compare this with survival in patients receiving systemic
therapy (ST) alone.
Methods: During 1996–2011, 24 patients who had failed to respond or had shown an incomplete
response to ST underwent laparoscopic RFA for LMBC. Outcomes in these patients were compared with
those in 32 patients with LMBC matched by tumour size and number, but treated with ST alone. Clinical
parameters and overall survival were compared using t-tests, chi-squared tests and Kaplan–Meier
analysis.
Results: The groups were similar in hormone receptor status and chemotherapy exposure. In the
laparoscopic RFA and ST groups, respectively, the mean  standard deviation size of the dominant liver
tumour and the number of tumours per patient were 3.7  0.4 cm and 2.4  0.4 cm, and 2.6  0.4
tumours and 3.3  0.4 tumours, respectively. These differences were not significant. At a median
follow-up of 20 months in the laparoscopic RFA group, 42% of patients were found to have developed
local liver recurrence, 63% had developed new liver disease and 38% had developed extrahepatic
disease. Overall survival after the diagnosis of liver metastasis was 47 months in the laparoscopic RFA
group and 9 months in the ST-only group (P = 0.0001). Five-year survival after the diagnosis of liver
metastasis was 29% in the RFA group and 0% in the ST-only group.
Conclusions: This is the first study to compare outcomes in RFA and ST, respectively, in LMBC. The
results show that survival after laparoscopic RFA plus ST is better than that after ST alone.
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Introduction
In the USA, breast cancer is the leading cause of cancer-related
death in women.1 More than 50% of these patients develop liver
metastases, 8.1% of which are isolated to the liver.2 Although
5-year survival in patients with disease localized to the breast
is 95%, this decreases to 50% in patients with metastatic
disease.1
Breast cancer with liver metastases is generally considered a
disseminated disease with a poor prognosis and is associated with
median survival of 6 months without treatment and 14–22
months with chemotherapy.2,3 In a minority of patients in whom
disease is limited to the liver, resection has been shown to result in
a median survival of 32 months and 5-year survival of 37%.4
In another subset of patients with predominant liver involve-
ment, locoregional treatment may be an important adjunct to
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systemic treatment and may improve survival.1 There are various
reports of the use of radiofrequency ablation (RFA) for liver
metastases from breast cancer (LMBC), predominantly in the
radiology literature.5–7 These studies have reported encouraging
results and 5-year survival of 27%.5–7 However, experience with
laparoscopic RFA is limited.5–7 Previous studies by the current
authors reported efficient local tumour control in hepatocellular
cancer, and in patients with metastases from colorectal and neu-
roendocrine tumours.8,9 The aim of this study was to compare
survival in patients with LMBC undergoing laparoscopic liver
RFA with that in patients treated with systemic therapy (ST)
alone.
Materials and methods
This study was approved by the institutional review board (IRB)
of the Cleveland Clinic Foundation. The RFA patients were part of
a prospective study evaluating the results of laparoscopic RFA in
patients with malignant liver tumours and hence their data were
collected prospectively.
Inclusion in the laparoscopic RFA group was subject to the
following criteria: (i) the presence of liver metastases from breast
cancer; (ii) no or minimal extrahepatic disease (EHD); (iii) <20%
of liver volume involvement by tumour, and (iv) no evidence of
biliary dilatation on computed tomography (CT) scans. Upon
referral to the RFA programme, patients underwent extensive
preoperative staging using abdominal, chest and brain CT scans,
as well as bone scans to rule out EHD. Patients with EHD were
treated with RFA only if the disease was limited and stable for6
months. The liver was evaluated with triphasic CT scans obtained
preoperatively and 1 week postoperatively. Patients were followed
up quarterly for the first 2 years and then biannually with abdomi-
nal and chest CT scans.
During 1996–2011, a total of 120 patients with LMBC under-
went ST alone. Data for these patients were extracted from an
IRB-approved prospective oncology registry and analysed retro-
spectively. Thirty-two of these patients were matched with the
RFA patients for liver tumour size (dominant tumour of <10 cm),
number of tumours (fewer than nine), and the interval between
the diagnoses of the primary disease and liver metastases (<24
months).
Surgical technique
The procedure was performed with the patient under general
anaesthesia. A diagnostic laparoscopy with biopsy of any suspi-
cious EHD was performed. Laparoscopic ultrasonography of the
liver was then performed, during which the sizes and locations of
all suspected tumours were determined. Under ultrasound guid-
ance, 18-gauge core biopsies of the representative lesions were
obtained using a spring-loaded biopsy gun in order to achieve
histological confirmation. The radiofrequency thermoablation
catheter was placed percutaneously into the lesion, and the tines
deployed under laparoscopic ultrasound guidance. The proce-
dures were performed using various ablation catheters and gen-
erators supplied by Angiodynamic, Inc. (Latham, NY, USA). The
ablation parameters were identical to those used to ablate hepa-
tocellular cancer and colorectal and neuroendocrine liver metas-
tases. All patients were monitored overnight and discharged to
home the morning after surgery.
Statistical analysis
Data were analysed using jmp Version 9.0 (SAS Institute, Inc.,
Cary, NC, USA). Demographic and clinical parameters were com-
pared using the Mann–Whitney U-test and the chi-squared test.
Overall and disease-free Kaplan–Meier survival analyses were per-
formed. Disease-free survival was calculated for the 16 patients in
the RFA group without EHD at the time of diagnosis.
Results
During 1996–2011, 910 patients underwent laparoscopic RFA of
liver tumours. Among these, 24 patients had LMBC. These
patients had received extensive chemotherapy and/or hormonal
therapy prior to their referral for RFA. All patients in both groups
were female. The RFA group included 24 patients with a total of 57
liver lesions who underwent a total of 35 laparoscopic RFA ses-
sions. The ST group included 32 patients with a total of 107 liver
lesions. One patient underwent concomitant resection of primary
breast disease and laparoscopic RFA of liver metastasis. Table 1
summarizes the demographic and clinical data for the study
groups.
The median follow-up in the RFA group was 20 months (range:
6–101 months). During this follow-up, 10 of the RFA patients
developed local liver recurrence at the site of ablation, 15 devel-
oped new liver disease and nine developed EHD. Local recurrence
per liver lesion treated with RFA was 19%. Repeat RFA (n = 10),
chemotherapy (n = 15) and liver resection (n = 1) were used to
obtain local tumour control for recurrences during follow-up. In
the RFA group, median disease-free survival was 9 months and
overall survival was 48 months from the diagnosis of liver metas-
tasis. Five-year actuarial survival was 29%. By contrast, in the
ST-only group, median follow-up was 27 months, overall survival
was 9 months and 5-year actuarial survival was 0% (Fig. 1).
Discussion
This study analysed a 15-year experience with laparoscopic RFA
for LMBC and compared findings in RFA patients with those in
patients treated with ST alone. This is the largest laparoscopic
series to be reported to date. The present group of patients with
predominantly liver disease showed encouraging results, demon-
strating a local tumour control rate of 81% and 5-year actuarial
survival of 29% after RFA, compared with 0% after ST alone.
Overall survival in patients who have liver deposits from breast
cancer at the time of the first chemotherapy cycle is 16.3 months
and the median time to disease progression is 7.9 months.10 If
metastasis is present at other sites, overall survival decreases from
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23–27 months to 14–17 months.2 The results of salvage chemo-
therapy in those patients who have not responded to prior chemo-
therapy are worse: median overall survival is 5–13 months and
time to progression is 4.4–9.1 months.11–13 These dismal results
underscore the need for additional treatment options for patients
with LMBC.
Surgical studies have shown that survival in LMBC can be
improved with hepatic resection rather than chemotherapy
alone.4,14 In the largest study of patients undergoing liver resection
(n = 85), 33% had EHD. Median survival was 32 months and
5-year survival was 37% during a 38-month median follow-up.
Median and 5-year disease-free survival were 20 months and 21%,
respectively. Twenty-eight patients developed liver recurrence, 22
developed liver disease plus EHD and nine developed EHD only.4
In a recent study conducted in the USA in a series of 31 patients
with LMBC subjected to liver resection, the median tumour size
was 2.9 cm and the median number of tumours was 1.7. Median
overall and disease-free survival were 25 months and 13 months,
respectively. Five-year actuarial survival was 61% and disease-free
survival was 31%.14
As a result of the encouraging results achieved in patients with
other tumour types, RFA has also been used for the treatment of
LMBC. Table 2 summarizes these studies.5,6,15–19 In general, the
Table 1 Demographic and clinical details of patients with breast cancer metastases to the liver
Parameters RFA group (n = 24) ST group (n = 32) P-value
Age, years, mean  SD (range; median) 50  2 (31–65; 51) 50  1.8 (28–73; 51) 0.968
Primary tumour pathology, n 0.728
Infiltrating ductal adenocarcinoma 22 28
Inflammatory cancer 1 1
Invasive lobular carcinoma 1 2
Medullary cancer 0 1
Oestrogen receptor status positive, n 6 14 0.144
Progesterone receptor status positive, n 4 11 0.132
HER-2 status positive, n 6 13 0.216
Interval between diagnosis of primary tumour and liver
metastasis, months, mean  SD (range; median)
26.5  5.6 (0–80; 23) 20.1  3.3 (0–73; 15) 0.307
Liver tumour site, n 0.131
Bilobar 10 13
Left lobe only 2 9
Right lobe only 11 10
Caudate lobe 1 0
Liver tumours per patient, mean  SD (range; median) 2.4  0.4 (1–9; 2) 3.3  0.4 (1–8; 3) 0.080
Dominant liver tumour size, cm, mean  SD (range; median) 3.7  0.4 (1–10; 3.4) 2.6  0.4 (0.4–9; 1.5) 0.064
RFA sessions per patient, mean  SD (range; median) 1.5  0.1 (1–3; 2) _
Type of chemotherapy 0.112
Anthracycline 11 19
Antimetabolite 2 0
Taxane 6 13
RFA, radiofrequency ablation; ST, systemic therapy; SD, standard deviation; HER-2, human epidermal growth factor receptor 2.
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Figure 1 Kaplan–Meier curves for overall survival in patients in the
laparoscopic radiofrequency ablation (RFA) group and the systemic
therapy (ST)-alone group. Median overall survival after the diagnosis
of liver metastases was 47 months in the RFA group and 9 months
in ST-alone group (P < 0.001)
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patient characteristics and oncologic results described in the
current study are similar to those reported in these earlier studies.
The interval between the diagnoses of, respectively, primary
disease and liver metastasis has been found to affect survival after
RFA of LMBC in some studies. In these studies, the interval found
to predict prognosis in a positive manner varied between 1 year
and 4 years.20–22 In the current study, the median interval was 27
months.
The management of patients with EHD and predominant liver
involvement is controversial. Some studies have excluded these
patients from liver ablation,14,23–25 whereas others, similarly to the
current study, have offered RFA.4–6,17–20,26 Different groups have
shown that limited amounts of EHD do not adversely affect sur-
vival in these patients.19,26 It is important to document the stability
of these extrahepatic deposits before committing to treat the liver
disease.
Despite the wider experience with percutaneous RFA reported
in the literature, the laparoscopic technique has a role in the
management of these patients because it provides the advantages
of abdominal exploration for more accurate staging, more precise
targeting of the lesions as a result of the immobilization of the
liver with pneumoperitoneum, and increased safety afforded by
the ability to retract the surrounding organs to prevent inadvert-
ent injuries. Four of the current patients underwent concomitant
cholecystectomy for lesions close to the gallbladder in order to
prevent a postoperative bile leak. The current study found no
complications associated with the laparoscopic technique, which
compares favourably with morbidity of 2.2–5.0% and mortality of
0.3% associated with percutaneous RFA.27
Because the current study did not include a comparison group
of resection patients, it is difficult to comment on whether RFA
may represent an alternative to resection in patients with resect-
able disease. Recently, Bergenfeldt et al. reviewed 25 surgical and
seven local ablation studies on LMBC and showed that median
survival after RFA (30–60 months) was similar to that reported
after resection (20–67 months).28 The low rate of complications
and high local tumour control rate suggest that laparoscopic RFA
should be considered among the liver-directed treatment options
for LMBC in appropriate patients. Patients with bulky tumours
that are not amenable to ablation should be directed to resection.
The overall survival of 47 months established in the current study
is comparable with rates reported in surgical series. The compli-
cation rate and the length of recovery time after hepatic resection
should not be underestimated. Patients in the current study
required only an overnight hospital stay.
In conclusion, this study reports that survival after laparoscopic
RFA plus ST was better than that after ST alone. Hence, these
findings support the proposal that patients with metastatic breast
cancer with predominantly liver involvement should be consid-
ered for locoregional treatment options, including RFA.
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